Trial · NCT02740660
Body Composition Changes With Albuterol and Caffeine Versus Placebo in Adolescents
NCT02740660, Not applicable, Completed, Pennington Biomedical Research Center; results first posted 2019-09-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Body Composition Changes With Albuterol and Caffeine Versus Placebo in Adolescents. Trials, record NCT02740660. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02740660
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Body Composition Changes With Albuterol and Caffeine Versus Placebo in Adolescents
- NCT number
- NCT02740660
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 12 participants, actual
- Lead sponsor
- Pennington Biomedical Research Center
- Conditions
- Pediatric Obesity
- Interventions
- Caffeine 100mg / Albuterol 4mg, Placebo, Family weight management counseling
- First posted
- 2016-04-15
- Last updated
- 2019-10-08
- Results first posted
- 2019-09-25
- Limitations and caveats
- This was a pilot study with a small number of participants. Diet and physical activity was not controlled in this pilot study.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Fat Mass With Caffeine/Albuterol | Baseline, Week 8 | DXA Scan of obese adolescents |
| Primary | Change in Lean Mass With Caffeine/Albuterol | Baseline, Week 8 | DXA Scan of obese adolescents |
| Primary | Change in Weight With Caffeine/Albuterol | Baseline, Week 8 | |
| Secondary | Number of Participants With Adverse Events | Week 2, Week 4, Week 6, Week 8 |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Fat Mass With Caffeine/Albuterol | Baseline, Week 8 | kg | MEAN | |
| PRIMARY | Change in Lean Mass With Caffeine/Albuterol | Baseline, Week 8 | kg | MEAN | |
| PRIMARY | Change in Weight With Caffeine/Albuterol | Baseline, Week 8 | kg | MEAN | |
| SECONDARY | Number of Participants With Adverse Events | Week 2, Week 4, Week 6, Week 8 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Fat Mass With Caffeine/Albuterol | Caffeine 100mg / Albuterol 4mg | 0.97 | Standard Deviation 1.11 | kg | |
| Change in Fat Mass With Caffeine/Albuterol | Placebo | -0.21 | Standard Deviation 1.41 | kg | |
| Change in Lean Mass With Caffeine/Albuterol | Caffeine 100mg / Albuterol 4mg | 1.34 | Standard Deviation 1.22 | kg | |
| Change in Lean Mass With Caffeine/Albuterol | Placebo | 0.88 | Standard Deviation 1.16 | kg | |
| Change in Weight With Caffeine/Albuterol | Caffeine 100mg / Albuterol 4mg | 2.57 | Standard Deviation 1.92 | kg | |
| Change in Weight With Caffeine/Albuterol | Placebo | 1.05 | Standard Deviation 2.19 | kg | |
| Number of Participants With Adverse Events | Caffeine 100mg / Albuterol 4mg | 5 | Participants | ||
| Number of Participants With Adverse Events | Placebo | 2 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Caffeine 100mg / Albuterol 4mg | 6 | |
| Overall Study | STARTED | Placebo | 6 | |
| Overall Study | COMPLETED | Caffeine 100mg / Albuterol 4mg | 6 | |
| Overall Study | COMPLETED | Placebo | 6 | |
| Overall Study | NOT COMPLETED | Caffeine 100mg / Albuterol 4mg | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Caffeine 100mg / Albuterol 4mg | 1 | 6 | 1 |
| other | Headache | Nervous system disorders | Placebo | 1 | 6 | 1 |
| other | Drowsiness | Nervous system disorders | Caffeine 100mg / Albuterol 4mg | 0 | 6 | 0 |
| other | Drowsiness | Nervous system disorders | Placebo | 1 | 6 | 1 |
| other | Palpitations | Cardiac disorders | Caffeine 100mg / Albuterol 4mg | 1 | 6 | 1 |
| other | Palpitations | Cardiac disorders | Placebo | 0 | 6 | 0 |
| other | Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | Caffeine 100mg / Albuterol 4mg | 1 | 6 | 1 |
| other | Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 6 | 0 |
| other | Tremor | Nervous system disorders | Caffeine 100mg / Albuterol 4mg | 1 | 6 | 1 |
| other | Tremor | Nervous system disorders | Placebo | 0 | 6 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Caffeine 100mg / Albuterol 4mg | 0 | 6 |
| Total, all-cause mortality | Placebo | 0 | 6 |
| Total, other adverse events | Caffeine 100mg / Albuterol 4mg | 5 | 6 |
| Total, other adverse events | Placebo | 2 | 6 |
| Total, serious adverse events | Caffeine 100mg / Albuterol 4mg | 0 | 6 |
| Total, serious adverse events | Placebo | 0 | 6 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Caffeine 100mg / Albuterol 4mg vs Placebo: deaths from any cause | Trial comparisons |
| Caffeine 100mg / Albuterol 4mg vs Placebo: Number of Participants With Adverse Events | Trial comparisons |
| Caffeine 100mg / Albuterol 4mg vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02740660
GET https://conductscience.org/api/trials/v1/NCT02740660/registered